Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May 10;40(14):1597-1598.
doi: 10.1200/JCO.22.00209. Epub 2022 Mar 8.

Reply to T. Olivier et al

Jedd D Wolchok  1 , Harriet Kluger  1 , Federico Campigotto  1 , James Larkin  1 , F Stephen Hodi  1
Affiliations
Comment

Reply to T. Olivier et al

Jedd D Wolchok et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Jedd D. WolchokStock and Other Ownership Interests: Tizona Therapeutics, Inc, Adaptive Biotechnologies, Imvaq Therapeutics, Beigene, Linnaeus Therapeutics, Arsenal IO, Georgiamune, LLC, Apricity Therapeutics, Maverick Therapeutics, and Trieza TherapeuticsConsulting or Advisory Role: Bristol Myers Squibb, Merck, Sellas Life Sciences, Lilly, Tizona Therapeutics, Inc, Amgen, Chugai Pharma, Adaptive Biotechnologies, Ascentage Pharma, PsiOxus Therapeutics, F-Star Biotechnology, Surface Oncology, Apricity Therapeutics, Astellas Pharma, Recepta Biopharma, Arsenal IO, Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo, Inc, Dragonfly Therapeutics, Georgiamune, Kyowa Kirin Pharmaceutical, Maverick Therapeutics, Werewolf Therapeutics, Trishula Therapeutics, Idera, Imvaq Therapeutics, Bicara TherapeuticsResearch Funding: Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Merck Sharp & Dohme (Inst)Patents, Royalties, Other Intellectual Property: I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals, I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus, I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells, I am co-inventor and receive royalties for a patent for immune modulating antibodies, I am a co-inventor on a patent for CAR + T cells targeting differentiation antigens as means to treat cancer, and I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy, Alphavirus Replicon Particles Expressing TRP2, Engineered Vaccinia Viruses for Cancer Immunotherapy, and Recombinant Poxviruses for Cancer Immunotherapy Harriet KlugerConsulting or Advisory Role: Nektar, Celldex, Iovance Biotherapeutics, Merck, ElevateBio, Instil Bio, Clinigen Group, Shionogi, Bristol Myers Squibb, ChemoCentryx, Calithera Biosciences, signateroResearch Funding: Merck (Inst), Bristol Myers Squibb (Inst), Apexigen (Inst)Travel, Accommodations, Expenses: Apexigen Federico CampigottoEmployment: Bristol Myers Squibb/Celgene/Juno, Gilead Sciences, GenentechStock and Other Ownership Interests: Bristol Myers Squibb/Celgene/Juno, Genentech James LarkinHonoraria: Bristol Myers Squibb, Pfizer, Novartis, Incyte, Merck Serono, Eisai, touchIME, touchEXPERTS, Royal College of Physicians, Cambridge Healthcare research, RCGP, VJOncology, Agence UnikConsulting or Advisory Role: Bristol Myers Squibb, Incyte, iOnctura, Apple Tree Partners, Merck Serono, Eisai, Debiopharm Group, Pierre Fabre, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude Health, AstraZeneca, GlaxoSmithKline, Calithera Biosciences, Ultimovacs, Seattle Genetics, eCancer, MCA, Inselgruppe, Pfizer, Goldman Sachs, MSD OncologyResearch Funding: Pfizer (Inst), Novartis (Inst), MSD (Inst), Bristol Myers Squibb (Inst), Achilles Therapeutics (Inst), Roche (Inst), Nektar (Inst), Covance (Inst), Immunocore (Inst), AVEO (Inst), Pharmacyclics (Inst)Travel, Accommodations, Expenses: Roche/Genentech, GlaxoSmithKline, Pierre Fabre F. Stephen HodiEmployment: Dana-Farber Cancer InstituteLeadership: Bicara TherapeuticsStock and Other Ownership Interests: Apricity Health, Torque, Pionyr, Bicara TherapeuticsConsulting or Advisory Role: Merck Sharp & Dohme, Novartis, Genentech/Roche, EMD Serono, Sanofi, Bristol Myers Squibb, Surface Oncology, Compass Therapeutics, Partners Therapeutics, Pionyr, Torque, Rheos Medicines, Boston Pharmaceuticals, Checkpoint THerapeutics, Eisai, Bioentre, Gossamer Bio, Iovance Biotherapeutics, Trillium Therapeutics, Catalym, Amgen, ImmunocoreResearch Funding: Bristol Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Genentech/Roche (Inst), novartis (Inst)Patents, Royalties, Other Intellectual Property: Patent pending as per institutional policy, patent pending royalties received on MICA related disorders application to institution per institutional IP policy, Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst), Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms, Methods of Using Pembrolizumab and Trebananib (Inst)Travel, Accommodations, Expenses: Novartis, Bristol Myers SquibbOther Relationship: Bristol Myers Squibb, Genentech/RocheNo other potential conflicts of interest were reported.

Comment on

References

    1. Olivier T, Prasad V: Frontline dual checkpoint inhibition in metastatic melanoma over anti–PD-1 monotherapy: The case for a comparative randomized controlled trial. J Clin Oncol 40:1596-1597, 2022 - PubMed
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. : Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127-137, 2022 - PMC - PubMed
    1. Weiss SA, Kluger H: CheckMate-067: Raising the bar for the next decade in oncology. J Clin Oncol 40:111-113, 2022 - PMC - PubMed
    1. Lipson EJ, Tawbi HA-H, Schadendorf D, et al. : Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224–047). J Clin Oncol 39, 2021. (suppl 15; abstr 9503)
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. : Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535-1546, 2019 - PubMed